Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03804268
Other study ID # 1883-301-013
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date December 21, 2018
Est. completion date October 31, 2019

Study information

Verified date November 2021
Source Allergan
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A study to evaluate the efficacy, safety, and pharmacokinetics of pilocarpine hydrochloride (HCl) ophthalmic solution (AGN-190584) when administered bilaterally, once daily for 30 days in participants with presbyopia.


Recruitment information / eligibility

Status Completed
Enrollment 323
Est. completion date October 31, 2019
Est. primary completion date October 31, 2019
Accepts healthy volunteers No
Gender All
Age group 40 Years to 55 Years
Eligibility Inclusion Criteria: - Subjective complaints of poor near vision that impact activities of daily living Exclusion Criteria: - History of cataract surgery, phakic intraocular lens surgery, corneal inlay surgery, radial keratotomy, or any intraocular surgery - Use of any topical ophthalmic medications, including artificial tears other than the study medications during the study - Use of temporary or permanent punctal plugs or history of punctal cautery in one or both eyes - Corneal abnormalities (including keratoconus, corneal scar, Fuchs' endothelial dystrophy, guttata, or edema) in either eye that are likely to interfere with visual acuity - Narrow iridocorneal angles (Shaffer grade =2 or lower on gonioscopy examination), history of angle-closure glaucoma, or previous iridotomy - Diagnosis of any type of glaucoma or ocular hypertension

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Vehicle
Vehicle, one drop in each eye, once daily, for up to 30 days.
Drug:
Pilocarpine HCl Ophthalmic Solution
Pilocarpine HCl ophthalmic solution 1.25%, one drop in each eye, once daily, for up to 30 days.

Locations

Country Name City State
United States Assil Eye Institute Beverly Hills California
United States The Eye Associates Bradenton Florida
United States Hill Country Eye Center Cedar Park Texas
United States Arizona Eye Center Chandler Arizona
United States Mundorf Eye Center Charlotte North Carolina
United States Haas Vision Center Colorado Springs Colorado
United States The Ohio State University Columbus Ohio
United States Scott & Christie and Associates, PC Cranberry Township Pennsylvania
United States Key-Whitman Eye Center Dallas Texas
United States Danbury Eye Physicians and Surgeons P.C. Danbury Connecticut
United States Bruce Segal, MD Delray Beach Florida
United States Hoopes, Durrie, Rivera Research Draper Utah
United States Seidenberg Protzko Eye Associates Havre De Grace Maryland
United States Direct Helpers Research Center Hialeah Florida
United States Research Centers of America Hollywood Florida
United States Price Vision Group Indianapolis Indiana
United States Tauber Eye Center Kansas City Missouri
United States Sabates Eye Centers Leawood Kansas
United States American Institute of Research Los Angeles California
United States The Eye Care Institute Louisville Kentucky
United States Florida Eye Associates Melbourne Florida
United States Southern College of Optometry Memphis Tennessee
United States Nashville Vision Associates Nashville Tennessee
United States Eye Research Foundation Newport Beach California
United States Devers Eye Institute Portland Oregon
United States Alterman, Modi & Wolter Poughkeepsie New York
United States EyeCare Professionals DWA Insight Research Clinic, LLC Powell Ohio
United States Martel Eye Medical Group Rancho Cordova California
United States Black Hills Regional Eye Institute Rapid City South Dakota
United States Rochester Ophthalmological Group, PC Rochester New York
United States Grutzmacher & Lewis, A Medical Corporation DBA Sacramento Eye Consultants Sacramento California
United States PNV Clinical Research LLC San Antonio Texas
United States R and R Eye Research, LLC San Antonio Texas
United States Schwartz Laser Eye Center Scottsdale Arizona
United States Vance Thompson Vision Sioux Falls South Dakota
United States USF Eye Institute Tampa Florida

Sponsors (1)

Lead Sponsor Collaborator
Allergan

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 3 Visual acuity for near (40 centimeters (cm)) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter (cd/m^2) measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. Baseline (Day 1) to Day 30 (Hour 3)
Secondary Percentage of Participants Gaining 3 Lines or More in Mesopic, High-contrast, Binocular Distance-Corrected Near Visual Acuity (DCNVA) at Day 30, Hour 6 Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. Baseline (Day 1) to Day 30 (Hour 6)
Secondary Percentage of Participants Gaining 3-lines or More in Mesopic, High-contrast, Binocular, DCNVA at Day 30, Hour 8 Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 candelas per square meter measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast DCNVA are reported. Baseline (Day 1) to Day 30 (Hour 8)
Secondary Change From Baseline in Mesopic, High-contrast, Binocular DCNVA Letters at Day 30, Hour 0.5 Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. Mixed effect model for repeated measures (MMRM) was used for analyses. Baseline (Day 1) to Day 30 (Hour 0.5)
Secondary Percentage of Participants Achieving 20/40 or Better in Photopic, High-contrast, Binocular, DCNVA at Day 30, Hour 1 Visual acuity for near (40 cm) target was measured in photopic conditions using an eye chart. Photopic condition was defined as high lighting =80 cd/m^2 measured at the target. Percentage of participants achieving 20/40 or better in photopic, high-contrast, binocular, DCNVA are reported. Day 30 (Hour 1)
Secondary Mean Change From Baseline in Mesopic Near Vision Presbyopia Task-based Questionnaire (NVPTQ) Performance Score at Day 30, Hour 3 NVPTQ had 12 questions on 4 reading tasks(reading a paragraph from book, excerpts from an article in newspaper, portion of a nutrition label, and a section from restaurant menu). Participants completed specific reading tasks under mesopic conditions without any near-vision correction and answered 3 questions for each task, rating their vision-related reading ability as 0=I could not read any text due to problems seeing up close,1=poor,2=fair,3=good,4=very good,5=excellent;impact of squinting on performance as 0=No,I did not squint, 1=Yes,squinting helped me read some/all text, 2=Yes,but I still could not read any of the text; and satisfaction as 0=very dissatisfied to 4=very satisfied. The score based on vision related ability and impact of squinting=(Book testlet+Newspaper testlet+Menu testlet+Nutrition Label testlet)/(testlets with non-missing responses), total possible score of 0-5. Higher scores=better outcomes;positive change from Baseline=improved performance(reading ability). Baseline (Day 1) to Day 30 (Hour 3)
Secondary Change From Baseline in Photopic, High-contrast, Binocular Distance-corrected Intermediate Visual Acuity (DCIVA) Letters at Day 30, Hour 3 Visual acuity for intermediate (66 cm) target was measured in photopic conditions using an eye chart. Photopic condition was defined as high lighting =80 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. MMRM was used for analyses. Baseline (Day 1) to Day 30 (Hour 3)
Secondary Percentage of Participants Gaining 3-lines or More in Mesopic, High-contrast, Binocular, DCNVA at Day 30, Hour 10 Visual acuity for near (40cm) target was measured in mesopic conditions using an eye chart. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2measured at the target. Percentage of participants with 3 lines or more improvement from Baseline in mesopic, high-contrast, binocular DCNVA are reported. Baseline (Day1) to Day 30 (Hour 10)
Secondary Change From Baseline in Mesopic, High-contrast, Binocular DCNVA Letters at Day 30, Hour 0.25 Visual acuity for near (40 cm) target was measured in mesopic conditions. Mesopic condition was defined as low lighting 3.2 to 3.5 cd/m^2 measured at the target. A positive change from Baseline indicates improvement in visual acuity. MMRM was used for analyses. Baseline (Day 1) to Day 30 (Hour 0.25)
Secondary Percentage of Participants Achieving 20/40 or Better in Photopic, High-contrast, Binocular, DCNVA at Day 30, Hour 3 Visual acuity for near (40 cm) target was measured in mesopic conditions using an eye chart. Photopic condition was defined as high lighting =80 cd/m^2 measured at the target. Percentage of participants achieving 20/40 or better in photopic, high-contrast, binocular, DCNVA are reported. Day 30 (Hour 3)
Secondary Mean Change From Baseline in Mesopic NVPTQ Satisfaction Score at Day 30, Hour 3 NVPTQ had 12 questions on 4 reading tasks(reading a paragraph from book, excerpts from an article in newspaper, portion of a nutrition label, and a section from restaurant menu). Participants completed specific reading tasks under mesopic conditions without any near-vision correction and answered 3 questions for each task, rating their vision-related reading ability as 0=I could not read any text due to problems seeing up close to 5=excellent; impact of squinting on performance as 0=No, I did not squint, 1=Yes, squinting helped me read some/all text, 2=Yes, but I still could not read any of the text; and satisfaction as 0=very dissatisfied,1=dissatisfied,2=neither satisfied nor dissatisfied,3=satisfied, 4=very satisfied. The score based on satisfaction items=(Book testlet+Newspaper testlet+Menu testlet+Nutrition Label testlet)/(testlets with non-missing responses) for a total possible score of 0 to 4. Higher scores=better outcomes; a positive change from Baseline=higher satisfaction. Baseline (Day 1) to Day 30 (Hour 3)
Secondary Mean Change From Baseline in Presbyopia Impact and Coping Questionnaire (PICQ) Coping Score at Day 30, Hour 3 PICQ=20 questions about impact experienced by participants due to their problems over past 7 days.PICQ Coping domain had 8 items: 1:Normal-sized text,2:Small-sized text,3:Information on a computer,4:Information on a cell phone,5:Increase font size,6:Use glasses to read close,12:Hold reading materials farther out/closer,13:Squint to read. Each item had response categories:0=never to 4=all the time. Items 3, 4, 5, and 6 had additional response categories with values of 9/10 to indicate the question is not applicable to participant and were assigned missing values.PICQ Coping Score:(Item 1,2 Testlet+Item 3,4 Testlet+Item 5+Item 6+Item 12+Item 13)/non-missing responses to the 6 components of coping score where Items 1,2 Testlet=(Item1+Item2)/non-missing responses to Items 1,2;Items 3,4 Testlet=(Item3+Item4)/non-missing responses to Items 3, 4. Score ranges:0=to least amount of coping to 4=greatest amount of coping. Higher scores=poorer outcome; a negative change from Baseline=improvement. Baseline (Day 1) to Day 30 (Hour 3)
Secondary Mean Change From Baseline in PICQ Impact Score at Day 30, Hour 3 PICQ had 20 questions about impact experienced by participants due to their problems seeing up over past 7 days. PICQ Impact domain had 6 items: Item 9:Rely on others,15:rest eyes,16:Feel older,17:Feel self-conscious,19:Take longer to complete a task,20:Inconvenient. First 5 impacts items included response categories: 0=never to 4=all the time. Item 20 had response categories: 0=not at all to 4=extremely. Item 9 included an additional response category with a value of 9 to indicate question was not applicable to participant and the responses were assigned missing values. PICQ Impacts Score=[(Item9+Item15+Items16,17Testlet+Item19+Item20)/(nonmissing responses to 5 components of impacts score)] where Items 16,17 Testlet=(Item16+Item17)/non-missing responses to Items 16 and 17. PICQ Impact score ranges from 0 to 4; with 0=least amount of impacts to 4=greatest amount of impacts. Higher scores correspond to poorer outcomes. A negative change from Baseline=improvement. Baseline (Day 1) to Day 30 (Hour 3)
See also
  Status Clinical Trial Phase
Completed NCT05326607 - Pilot Clinical Investigation of Adaptative Eyeglasses for the Correction of Presbyopia N/A
Recruiting NCT06060041 - IC-8 Apthera IOL New Enrollment Post Approval Study
Completed NCT05495971 - Extended Depth of Focus Contact Lenses for Presbyopia N/A
Completed NCT05464732 - Vivity IOL: Emmetropia Compared to Monovision. N/A
Recruiting NCT06045299 - Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia Phase 3
Active, not recruiting NCT04151550 - Safety & Efficacy of the Laser Scleral Microporation Procedure (Philippines) N/A
Not yet recruiting NCT05506553 - Comparison of Aspheric Toric Intraocular Lenses for Micro-monovision N/A
Completed NCT02554396 - Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia Phase 2
Completed NCT02235831 - DAILIES® AquaComfort Plus® Multifocal (MF) - Comparative Assessment of Visual Performance N/A
Completed NCT02214797 - Dispensing Study to Assess Visual Performance of Prototype Contact Lenses N/A
Enrolling by invitation NCT01443585 - Clinical Evaluation of a Progressive Addition Lens (PAL) N/A
Completed NCT01591499 - Clinical Evaluation of Biofinity Multifocal Compared With Air Optix Aqua Multifocal and With PureVision Multifocal N/A
Completed NCT04983589 - A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily Phase 3
Completed NCT02740010 - The Visual Performances of a Progressive Multifocal Intraocular Lens With Extended Depth of Focus
Recruiting NCT05796453 - Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix N/A
Completed NCT02516306 - A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia Phase 1/Phase 2
Completed NCT05359380 - The Impact of Light Conditions on the Efficacy of Multifocal Intraocular Lens Implantation in Activities of Daily Living
Not yet recruiting NCT04522427 - Study of Presbyopia-correcting Intraocular Lenses in Eyes With Previous Corneal Refractive Surgery N/A
Completed NCT03688425 - Comparison of Clinical Outcomes POD L GF vs POD F GF in Asian Eyes N/A
Recruiting NCT06053463 - Evaluation of Soft Multifocal Lenses in Presbyopic Previous Contact Lens Wearers N/A